InSphero launches 3D InSight™ gastrointestinal toxicity screening platform

14 April 2026

Zurich, Switzerland-based CRO InSphero, the global leader in 3D cell-based assays and organ-on-chip systems, announces the commercial launch of the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput screening solution for early assessment of gastrointestinal (GI) liabilities in drug discovery.

Despite efforts to flag GI toxicity risk early in the drug discovery process, DIGIT remains among the most common causes of late-stage clinical attrition. This latest addition to the InSphero product range was designed to address the need for scalable GI toxicity in vitro assays that reliably predict GI risk.

Key features of the 3D InSight™ include: human-relevant, patient-derived small intestinal organoids recapitulating native epithelial architecture, standardized monthly batch execution ensuring consistent data quality across studies, scalable throughput via Gri3D® technology and automated imaging, decision-ready IC₅₀ values with optional functional swelling readouts, simplified customer contracting, and seamless combination with 3D InSight™ DILI service for integrated hepatic and gastrointestinal safety profiling.

The launch marks a significant milestone in the integration of DOPPL SA, the Swiss organoid specialist acquired by InSphero.  

“When we acquired DOPPL, the vision was clear: combine their expertise in patient-derived intestinal organoids with our proven operational model for standardized safety screening. Today, that vision is reality. This is not a rebranding exercise. Our teams have built a genuinely integrated solution that brings the same rigor and ease of use that made our DILI service a gold standard to an entirely new organ system. For our customers, this means one partner, one contract, consistent data quality, and a clear path from compound submission to safety decision.” said David Fluri, VP Model Innovation and Commercialization, InSphero AG.

“At DOPPL, we spent years developing intestinal organoid technologies that capture human gut biology with unprecedented fidelity. Joining InSphero  enabled us to transform bespoke high-quality science into standardized solutions supported by a robust commercial infrastructure. The DIGIT platform is the product of true collaboration between our teams, and  marks an important step toward operational maturity for this type of organoid models. Ultimately, our goal is to enable reliable human safety testing across a range of organoid models at the preclinical stage, improving the quality and predictive power of next-generation NAMs.” said Sylke Hoehnel-Ka, CEO and Co-Founder, DOPPL SA.

For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.

Explore Access